Precipio, Inc. (NASDAQ:PRPO) Short Interest Update

Precipio, Inc. (NASDAQ:PRPO) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 12,800 shares, an increase of 19.6% from the February 28th total of 10,700 shares. Based on an average daily trading volume, of 9,400 shares, the short-interest ratio is presently 1.4 days. Approximately 1.0% of the shares of the stock are short sold.

Precipio Price Performance

Shares of Precipio stock traded down $0.23 on Thursday, hitting $5.33. 786 shares of the company traded hands, compared to its average volume of 7,859. Precipio has a 12-month low of $4.31 and a 12-month high of $10.74. The company has a current ratio of 0.73, a quick ratio of 0.60 and a debt-to-equity ratio of 0.02. The company has a market cap of $7.89 million, a P/E ratio of -2.91 and a beta of 1.37. The firm’s 50-day simple moving average is $7.05 and its 200 day simple moving average is $6.48.

Precipio (NASDAQ:PRPO) last announced its quarterly earnings data on Thursday, March 27th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.97). The firm had revenue of $5.45 million for the quarter, compared to analysts’ expectations of $8.01 million. Precipio had a negative net margin of 17.23% and a negative return on equity of 34.01%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Precipio stock. Renaissance Technologies LLC bought a new position in shares of Precipio, Inc. (NASDAQ:PRPO) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 10,100 shares of the biotechnology company’s stock, valued at approximately $56,000. Renaissance Technologies LLC owned 0.68% of Precipio at the end of the most recent quarter. 10.45% of the stock is currently owned by institutional investors.

Precipio Company Profile

Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.